$RLYB
Rallybio Corp

2023 Q4 Form 10-Q Financial Statement

#000173941023000014 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.188M $6.080M
YoY Change -17.62% -9.93%
% of Gross Profit
Research & Development $15.92M $13.29M
YoY Change 47.54% 9.73%
% of Gross Profit
Depreciation & Amortization $36.00K $30.00K
YoY Change -7.69% -28.57%
% of Gross Profit
Operating Expenses $21.11M $19.36M
YoY Change 23.53% 2.67%
Operating Profit -$19.36M
YoY Change 2.67%
Interest Expense $1.448M $1.550M
YoY Change 35.2%
% of Operating Profit
Other Income/Expense, Net $35.00K $1.637M
YoY Change 12.9% 162.76%
Pretax Income -$20.24M -$17.73M
YoY Change 24.93% -2.8%
Income Tax
% Of Pretax Income
Net Earnings -$20.24M -$18.37M
YoY Change 24.93% 0.02%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45
Diluted Earnings Per Share -$0.50 -$0.45
COMMON SHARES
Basic Shares Outstanding 37.79M shares 37.80M shares
Diluted Shares Outstanding 40.53M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $109.9M $121.4M
YoY Change -34.95% -8.32%
Cash & Equivalents $24.49M $19.16M
Short-Term Investments $85.44M $102.2M
Other Short-Term Assets $2.054M $3.592M
YoY Change 95.62% 205.44%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $114.8M $132.4M
YoY Change -36.05% -7.03%
LONG-TERM ASSETS
Property, Plant & Equipment $246.0K $282.0K
YoY Change -36.1% -33.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $239.0K $100.0K
YoY Change 696.67% -59.02%
Other Assets
YoY Change
Total Long-Term Assets $831.0K $772.0K
YoY Change -11.5% -37.59%
TOTAL ASSETS
Total Short-Term Assets $114.8M $132.4M
Total Long-Term Assets $831.0K $772.0K
Total Assets $115.6M $133.2M
YoY Change -35.92% -7.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $976.0K $464.0K
YoY Change -12.39% -43.96%
Accrued Expenses $8.068M $8.721M
YoY Change -14.62% -15.35%
Deferred Revenue $0.00
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.263M $9.402M
YoY Change -13.78% -16.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $173.0K $200.0K
YoY Change -53.74% -53.27%
Total Long-Term Liabilities $173.0K $200.0K
YoY Change -53.74% -53.27%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.263M $9.402M
Total Long-Term Liabilities $173.0K $200.0K
Total Liabilities $9.436M $9.613M
YoY Change -15.13% -18.0%
SHAREHOLDERS EQUITY
Retained Earnings -$235.2M -$215.0M
YoY Change 46.36% 48.81%
Common Stock $4.000K $4.000K
YoY Change 0.0% 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $106.2M $123.6M
YoY Change
Total Liabilities & Shareholders Equity $115.6M $133.2M
YoY Change -35.92% -7.29%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$20.24M -$18.37M
YoY Change 24.93% 0.02%
Depreciation, Depletion And Amortization $36.00K $30.00K
YoY Change -7.69% -28.57%
Cash From Operating Activities -$11.65M -$16.47M
YoY Change -23.71% 11.77%
INVESTING ACTIVITIES
Capital Expenditures $12.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $16.92M $3.070M
YoY Change -155.21% -46.85%
Cash From Investing Activities $16.91M $3.070M
YoY Change -155.18% -46.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 72.00K 0.000
YoY Change -99.86% -100.0%
NET CHANGE
Cash From Operating Activities -11.65M -16.47M
Cash From Investing Activities 16.91M 3.070M
Cash From Financing Activities 72.00K 0.000
Net Change In Cash 5.336M -13.40M
YoY Change 1.7% 48.2%
FREE CASH FLOW
Cash From Operating Activities -$11.65M -$16.47M
Capital Expenditures $12.00K $0.00
Free Cash Flow -$11.66M -$16.47M
YoY Change -23.63% 11.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37620000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29896000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6075000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6750000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20200000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20897000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
19363000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
18860000 usd
us-gaap Operating Expenses
OperatingExpenses
57820000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-50793000 usd
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
525000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
4699000 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
892000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
92000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
98000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
227000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
311000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1637000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
623000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1203000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-17726000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-18237000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-52894000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-49590000 usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-648000 usd
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-133000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1428000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-861000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18374000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18370000 usd
us-gaap Net Income Loss
NetIncomeLoss
-54322000 usd
us-gaap Net Income Loss
NetIncomeLoss
-50451000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40531497 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30777797 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30777797 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40382625 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40382625 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30562723 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30562723 shares
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
64000 usd
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-63000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
6000 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-434000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
64000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-63000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-434000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18310000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18433000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54316000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50885000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2504000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2017183 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
185990 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
107990 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
13.62
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37800856 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37800856 shares
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19363000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4926000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.65
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40531497 shares
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18370000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-63000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
131943000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
139257000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2634000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18374000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
64000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
123581000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
175602000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7205000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000 usd
us-gaap Net Income Loss
NetIncomeLoss
-50451000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-434000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
131943000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
169317000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8371000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
209000 usd
us-gaap Net Income Loss
NetIncomeLoss
-54322000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
123581000 usd
us-gaap Net Income Loss
NetIncomeLoss
-54322000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
114000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
128000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-2432000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
27000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8371000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7205000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1428000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-861000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
400000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3948000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-623000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
95000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-756000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4063000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48620000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42020000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
95675000 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
136670000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
107924000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
55500000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
54000 usd
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
1500000 usd
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
300000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10749000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-81524000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
209000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
138000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
100000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
71000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-79000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37800000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-123623000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56958000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
175334000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19158000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51711000 usd
rlyb Offering Costs In Accounts Payable And Accrued Expenses
OfferingCostsInAccountsPayableAndAccruedExpenses
0 usd
rlyb Offering Costs In Accounts Payable And Accrued Expenses
OfferingCostsInAccountsPayableAndAccruedExpenses
294000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
12000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
121400000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
108598000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
222000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
108390000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
128879000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
37000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
251000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
128665000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10502000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
108390000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
128665000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
92138000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
127667000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
16252000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
998000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
108390000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
128665000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
81000000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
70000000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2023Q3 rlyb Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
6420000 usd
CY2022Q4 rlyb Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
7904000 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
645000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
933000 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
381000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
615000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3592000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1050000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11038000 usd
CY2023Q3 rlyb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4679000 usd
CY2022Q4 rlyb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3582000 usd
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3328000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4703000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
396000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
510000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
318000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
654000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8721000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9449000 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37800856 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37800856 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37837369 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37837369 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2634000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2504000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8371000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7205000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2609314 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.01
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4332517 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1380083 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.80
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.99
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
19200000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2023Q3 rlyb Termination Charges
TerminationCharges
0 usd
CY2022Q4 rlyb Termination Charges
TerminationCharges
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-18374000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18370000 usd
us-gaap Net Income Loss
NetIncomeLoss
-54322000 usd
us-gaap Net Income Loss
NetIncomeLoss
-50451000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40531497 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40531497 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30777797 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30777797 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40382625 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40382625 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30562723 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30562723 shares
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.60
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.35
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.65

Files In Submission

Name View Source Status
rlyb-20230930_cal.xml Edgar Link unprocessable
0001739410-23-000014-index-headers.html Edgar Link pending
0001739410-23-000014-index.html Edgar Link pending
0001739410-23-000014.txt Edgar Link pending
0001739410-23-000014-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rlyb-20230930.htm Edgar Link pending
rlyb-20230930.xsd Edgar Link pending
rlyb-20230930xex311.htm Edgar Link pending
rlyb-20230930xex312.htm Edgar Link pending
rlyb-20230930xex321.htm Edgar Link pending
rlyb-20230930xex322.htm Edgar Link pending
rlyb-20230930_g1.jpg Edgar Link pending
Show.js Edgar Link pending
rlyb-20230930_def.xml Edgar Link unprocessable
rlyb-20230930_pre.xml Edgar Link unprocessable
rlyb-20230930_lab.xml Edgar Link unprocessable
rlyb-20230930_htm.xml Edgar Link completed